Page 31 - THE SOUTH CHINA BUSINESS JOURNAL
P. 31
C ommunity News
Caption: To date,
Gilead has introduced
8 innovative
therapeutics to China
in the areas of HBV,
HCV and HIV to
help address unmet
medical needs.
hepatitis, hematology/oncology, company has launched a phase 3 trial in China in
inflammatory and respiratory diseases. parallel with other global clinical trials on DKD,
expecting to synchronize the innovative medicines’
Bringing innovative approval in China with other international markets.
therapeutics to
patients in China With a strong portfolio in China of innovative
medicines for HBV, HCV and HIV/AIDS and a robust
There are estimated 10 million pipeline for even broader therapeutic areas for
people living with HCV in China the future, Gilead is making every effort to ensure
– one of the largest patient that local patients can be treated with innovative
populations in the world, and an therapeutics as early as possible.
estimated 86 million people living
with HBV, accounting for nearly Gilead pursues science to transform and simplify
one-third of global chronic HBV care for people with life-threatening illness.
infections. In 2018, approximately However, they believe it takes more than medicine
150,000 people were newly to improve people’s health and quality of life. The
diagnosed with HIV. company is working hard to enhance their abilities
to address the biggest health challenges on all fronts
Gilead is committed to bringing by collaborating even more closely with various
the best possible therapeutics to partners in China.■
the most patients in China within
the shortest time. This is not Caption: Aerial photo taken at the 2019 Gilead China Annual Meeting in Sanya, Hainan
just about always work hard to
significantly shorten the time span
between drug approval to patient
delivery. Their efforts start from
as early as clinical trials to prepare
for the approval. With a growing
population of diabetics worldwide,
the prevalence of diabetic kidney
disease (DKD), one of the major
causes of end-stage renal disease,
is also increasing. Given so, the
South China Business Journal 28
Caption: To date,
Gilead has introduced
8 innovative
therapeutics to China
in the areas of HBV,
HCV and HIV to
help address unmet
medical needs.
hepatitis, hematology/oncology, company has launched a phase 3 trial in China in
inflammatory and respiratory diseases. parallel with other global clinical trials on DKD,
expecting to synchronize the innovative medicines’
Bringing innovative approval in China with other international markets.
therapeutics to
patients in China With a strong portfolio in China of innovative
medicines for HBV, HCV and HIV/AIDS and a robust
There are estimated 10 million pipeline for even broader therapeutic areas for
people living with HCV in China the future, Gilead is making every effort to ensure
– one of the largest patient that local patients can be treated with innovative
populations in the world, and an therapeutics as early as possible.
estimated 86 million people living
with HBV, accounting for nearly Gilead pursues science to transform and simplify
one-third of global chronic HBV care for people with life-threatening illness.
infections. In 2018, approximately However, they believe it takes more than medicine
150,000 people were newly to improve people’s health and quality of life. The
diagnosed with HIV. company is working hard to enhance their abilities
to address the biggest health challenges on all fronts
Gilead is committed to bringing by collaborating even more closely with various
the best possible therapeutics to partners in China.■
the most patients in China within
the shortest time. This is not Caption: Aerial photo taken at the 2019 Gilead China Annual Meeting in Sanya, Hainan
just about always work hard to
significantly shorten the time span
between drug approval to patient
delivery. Their efforts start from
as early as clinical trials to prepare
for the approval. With a growing
population of diabetics worldwide,
the prevalence of diabetic kidney
disease (DKD), one of the major
causes of end-stage renal disease,
is also increasing. Given so, the
South China Business Journal 28
